Table 2.
Cell proliferation (CCK-8 assay), apoptosis, cell invasion and cell migration (wound healing rate) in the gastric adenocarcinoma cell line AGS following erlotinib treatment and/or transfection with small hairpin (sh)RNA targeting focal adhesion kinase (FAK).
| Parameter | Group |
||||
|---|---|---|---|---|---|
| A | B | C | D | E | |
| CCK-8 assay | |||||
| 24h | 0.75 ± 0.03 | 0.74 ± 0.02 | 0.53 ± 0.06a | 0.56 ± 0.04a | 0.34 ± 0.04ab |
| 48h | 1.36 ± 0.01 | 1.41 ± 0.12 | 0.94 ± 0.12a | 0.88 ± 0.08a | 0.51 ± 0.03ab |
| 72h | 1.77 ± 0.17 | 1.83 ± 0.13 | 1.05 ± 0.10a | 0.78 ± 0.08a | 0.42 ± 0.03ab |
| 96h | 2.14 ± 0.20 | 2.10 ± 0.21 | 1.19 ± 0.12a | 0.65 ± 0.03a | 0.34 ± 0.05ab |
| Apoptosis Rate, % | 7.3 ± 3.2 | 7.3 ± 2.0 | 35.0 ± 4.7a | 45.2 ± 4.2a | 59.1 ± 6.5ab |
| Cell invasion | 65.8 ± 0.8 | 64.6 ± 0.9 | 51.2 ± 1.3a | 21.7 ± 0.6a | 13.7 ± 1.2ab |
| Wound healing rate, % | 21.1 ± 0.9 | 21.3 ± 0.4 | 15.2 ± 0.8a | 12.8 ± 0.6a | 5.8 ± 0.6ab |
Data presented as mean ± SD.
a
P < 0.05 vs Group A;
b
P < 0.05 vs Group C and D; one-way analysis of variance.
Group A, control group (nontransfected, no erlotinib); Group B, empty vector group (transfected with empty vector, no erlotinib); Group C, FAK group (transfected with FAK-shRNA, no erlotinib); Group D, erlotinib group (nontransfected, 40 µmol/l erlotinib); Group E, combination group (transfected with FAK-shRNA, 40 µmol/l erlotinib)